TNFRSF17 and plasma cell myeloma: Belantamab-mafodotin, an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), shows good overall response rates of at least 40% in heavily pretreated myeloma patients but responses are mostly short-lived with a median progression-free survival (PFS) of around 3 to 4 months in real-world cohorts [3–6] and no PFS benefit compared to pomalidomide/dexamethasone in the randomized DREAMM-3 trial [7].